A Cross-Sectional Survey of Oral Adverse Events and Oral Management Needs in Outpatients Receiving Cancer Drug Therapy
Open Access
Abstract
Objectives: The aim of this study was to investigate the incidence and severity of oral adverse events in outpatients receiving cancer drug therapy and the need for oral management by medical professionals. Methods: A questionnaire-based survey was conducted among patients who received cancer drug therapy at our hospital between 1 and 30 September 2022. The incidence and severity of oral adverse events and the need for intervention by medical professionals were investigated. The risk factors for these events were also analyzed. Results: Of the 216 patients who answered the questionnaire, 127 (58.8%) experienced oral adverse events such as dysgeusia, oral mucositis, and xerostomia. Of the patients who experienced oral adverse events, 53.5% expressed that they wanted to improve their condition, 34.6% expressed that the adverse events affected their quality of life, and 26.8% wanted dental intervention. Thirty-two patients (25.2%) reported that the symptoms of these oral events were as severe as or more severe than those of other adverse events. The incidence of adverse oral events was significantly higher in patients treated with 5FU- and taxane-based regimens than in patients treated with other regimens. Conclusions: Our results suggest that cancer drug therapy, and the frequency and severity of oral adverse events, have a significant impact on the outpatients’ quality of life. More than a quarter of outpatients receiving cancer drug therapy wanted oral management through dental interventions. In particular, patients receiving 5FU-, taxane-, and anthracycline-based regimens may require oral management by medical professionals.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancerBreast Cancer Research and Treatment, 2020
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2020
- Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatmentSupportive Care in Cancer, 2018
- The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic reviewSupportive Care in Cancer, 2016
- Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2016
- Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategiesSupportive Care in Cancer, 2012
- Progress of oral care and reduction of oral mucositis—a pilot study in a hematopoietic stem cell transplantation wardSupportive Care in Cancer, 2010
- A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of lifeSupportive Care in Cancer, 2010
- Periodontal infection in cancer patients treated with high-dose chemotherapySupportive Care in Cancer, 2002
- Food avoidance in patients undergoing cancer chemotherapySupportive Care in Cancer, 1993